Once-daily treatment for canine atopic dermatitis
Delivers 6-in-1 parasite protection for cats
Valuable discounts, expert information, and tips
See how injectable medications offer value beyond the prescription
The first and only FDA-Approved veterinary antiemetic
The first long-lasting monoclonal antibody therapy for canine atopic dermatitis
Vaccination for the prevention of respiratory disease caused by BRSV
The beef industry’s No. 1 branded preconditioning program
Exclusive pricing program for Cattle producers
Outstanding protection against costly respiratory and reproductive diseases
Treatment and control of gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites
Innovative food safety products that help deliver a farm-to-fork solution for beef
The most comprehensive guarantee available
First and only FDA-approved antibiotic for horses that offers a full course of therapy in just two doses
Annual vaccination with CORE EQ INNOVATOR helps provide the protection your horse needs
Treats and controls encysted small strongyles, bots and roundworms. QUEST PLUS contains an additional active ingredient for efficacy against tapeworms
Patented and scientific method of determining fair service pricing to improve your clinic's profitability
Connect directly to valuable dairy management resources and experts
The most "veterinarian recommended" and "producer used" prostaglandin in the market
Delivers the peace of mind and profitability that come with no milk discard
Effective and convenient treatment for acute metritis in cattle
Working together to improve reproduction
One injection treats and controls swine respiratory disease for 7 days
Protect sows and gilts from costly breeding herd diseases — parvovirus, leptospirosis and erysipelas
The industry standard for in ovo technology.
Full automation solutions for hatchery automation
Prevention and control of necrotic enteritis, increased rate of weight gain and improved feed efficiency in poultry
for the prevention of coccidiosis in poultry
modified-live vaccine that helps poultry companies reduce their overall Salmonella load
Blood glucose monitoring system
Smart new diagnostics platform that can reinvent your in-house diagnostic routines
Detect Johne’s Disease with confidence in cattle and goat herds
Simple and effective detection of a deadly Feline Virus
Accurate, affordable and easy to use
Order Beef Genetics products online
Order Dairy Genetics products online
Delivers reliable predictions of genetic merit based on test results of core traits
Represents the latest advancement in Angus genotyping technology.
Register today to learn more
Become a more effective leader
Looking for a tailored experience?
Earn continuing education credits and stay current on industry developments with Zoetis’ convenient, on-demand learning solutions.
Veterinarians, Veterinarian Techs, Business Owners, and Farm Hands
Launch your veterinary career
Veterinarian Students and Recent Graduates
Animal health expertise and results-focused resources for high-performing teams and leaders.
Veterinarians, Dairy producers, Beef producers, Equine Specialists, Pork producers, Poultry producers, Managers, Business Owners and Staff
Home / NEWS & MEDIA / Pfizer Animal Health to Expand Access to E. coli O157 Vaccine from Epitopix for Beef Cattle
FOR IMMEDIATE RELEASE
NEW YORK, June 11, 2010 — Pfizer Animal Health today furthered its commitment to safe
food from cattle by announcing a global licensing agreement with Epitopix that will expand
access to its conditionally licensed Escherichia Coli Bacterial Extract vaccine* to U.S. cattle
producers this fall.
“Pfizer Animal Health supports cattle producers’ continuing strides against harmful
bacteria, often the most frequent causes of food borne illnesses in people,” said Juan Ramón
Alaix, president, Pfizer Animal Health. “We want more cattle producers to benefit from this
important vaccine to help reduce the prevalence and shedding of E. coli.”
The U.S. Department of Agriculture (USDA) granted a conditional license last year to
Epitopix for this first and only Escherichia Coli Bacterial Extract vaccine available in the U.S. It
is labeled for use in cattle to help reduce the prevalence of E. coli O157 in cattle and feces.
This helps to minimize E. coli exposure and infection of herd-mates.
As part of its licensing agreement, Pfizer Animal Health also acquired global rights to
Epitopix’ conditionally licensed Salmonella Newport bacterial extract vaccine*. Currently
available in the U.S. from Agri Laboratories, Ltd., of St. Joseph, Missouri under a USDA
conditional license, it will become an exclusive part of Pfizer Animal Health’s livestock portfolio
in the U.S. beginning in 2011
Pfizer Animal Health and Epitopix will conduct additional potency and efficacy studies
on both vaccines to secure a full license for each from the USDA. Terms of the global licensing
agreement were not disclosed.
“The R&D strength, global reach, and marketing expertise of Pfizer Animal Health make
it an ideal partner for Epitopix,” said Epitopix General Manager Jim Sandstrom. “By working in
close cooperation, our mutual aim is to quickly broaden the availability of these important
vaccines to the beef and dairy industries, as part of Pfizer Animal Health’s comprehensive
portfolio of cattle products and services.”
About E. coli Infection in People
The U.S. Centers for Disease Control (CDC) estimates approximately 70,000 cases
occur in people annually. However, the CDC acknowledges that most cases of E. coli O157 go
unreported. The symptoms of E. coli O157 infections vary for each person but often include
severe stomach cramps, diarrhea (often bloody), and vomiting. If there is fever, it usually is not
very high (less than 101˚F/less than 38.5˚C). Most people get better within 5–7 days. Some
infections are very mild, but others are severe or even life-threatening.
Epitopix LLC was founded in 2002 as an affiliate of Willmar Poultry Company, a
subsidiary of Life-Science Innovations headquartered in Willmar, Minn. at the MinnWest
Technology Campus, a 110 acre privately-owned technology business park. The mission of
Epitopix is to provide the food animal industry with novel bacterial vaccines with the potential to
be more broadly cross-protective and safer than conventional whole-cell bacterins or live
bacterial vaccines. Epitopix owns a family of patents related to the utilization of bacterial ironacquisition
proteins for use as vaccine antigens. For more information, visit www.Epitopix.com.
About Pfizer Animal Health
Pfizer, Inc, the world’s largest research-based biomedical and pharmaceutical company,
also is a world leader in discovering and developing innovative animal vaccines and
prescription medicines, investing an estimated $300 million annually. In the first quarter of
2010, Pfizer Animal Health generated revenue of $846 million, and for full-year 2009, $2.8
billion, including revenue from Wyeth/Fort Dodge since Pfizer’s acquisition in October.
In addition to helping assure a safe, global food supply from healthy food animals, Pfizer
Animal Health also helps dogs, cats and horses to live healthy longer. For additional
information on Pfizer’s portfolio of animal products and services, visit
*Notice: This product license is conditional. Efficacy and/or potency of this product have not
been fully demonstrated. Consultation with a veterinarian is recommended.
©2010 Pfizer Animal Health. All rights reserved. GCA10053.
Mon–Fri, 8am–8pm ET
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.
This site is intended for U.S. Animal Healthcare Professionals.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2017 Zoetis Services LLC. All rights reserved.